| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Betamethasone Valerate (BV; BET; Betoid; Valison; 9α-Fluo; Valisone; Bedermin; Betneval; Beta-Val; Bextasol; Dermosol; Stanoval) is a moderately potent and commonly used glucocorticoid steroid with anti-inflammatory and immunosuppressive activities. Betamethasone valerate is approved as an anti-inflammatory corticosteroid for topical applications.
| ln Vitro |
|
|
|---|---|---|
| ln Vivo |
When applied to the inflamed region using a microspatula, bebemethasone valerate (10 mg) ointment for five minutes controls approximately fifty percent of the ear edema without causing thymus atrophy[4]. Ointment containing 50 mg of betamethasone-17-valerate reduces homologous passive cutaneous anaphylaxis [4].
|
|
| Animal Protocol |
Animal/Disease Models: Female SD (Sprague-Dawley) rats weighing 60-70 g (croton oil edema experiment)[4]
Doses: 10 mg Route of Administration: Applied to the irritated site with a micro spatula; 5 minutes Experimental Results: Inhibited about 50% of the ear edema without thymus atrophy. |
|
| References |
[1]. Sizílio RH, et al. Chitosan/pvp-based mucoadhesive membranes as a promising delivery system of betamethasone-17-valerate for aphthous stomatitis. Carbohydr Polym. 2018 Jun 15;190:339-345.
[2]. Epstein EH Jr, et al. Glucocorticoid receptors of normal human epidermis. J Invest Dermatol. 1982 Feb;78(2):144-6. [3]. WILLIAMS DI, et al. BETAMETHASONE 17-VALERATE: A NEW TOPICAL CORTICOSTEROID. Lancet. 1964 May 30;1(7344):1177-9. [4]. Iizuka Y, et al. Two simple methods for the evaluation of topically active anti-inflammatory steroidal ointments. Agents Actions. 1981 May;11(3):254-9. |
| Molecular Formula |
C27H37FO6
|
|
|---|---|---|
| Molecular Weight |
476.58
|
|
| CAS # |
2152-44-5
|
|
| Related CAS # |
Betamethasone;378-44-9;Betamethasone hydrochloride;956901-32-9
|
|
| SMILES |
F[C@@]12[C@]3(C([H])=C([H])C(C([H])=C3C([H])([H])C([H])([H])[C@@]1([H])[C@]1([H])C([H])([H])[C@]([H])(C([H])([H])[H])[C@](C(C([H])([H])O[H])=O)([C@@]1(C([H])([H])[H])C([H])([H])[C@]2([H])O[H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)=O)C([H])([H])[H]
|
|
| InChi Key |
SNHRLVCMMWUAJD-SUYDQAKGSA-N
|
|
| InChi Code |
InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1
|
|
| Chemical Name |
(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl pentanoate
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0983 mL | 10.4914 mL | 20.9828 mL | |
| 5 mM | 0.4197 mL | 2.0983 mL | 4.1966 mL | |
| 10 mM | 0.2098 mL | 1.0491 mL | 2.0983 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA